Author: Allen Wilbanks

… The recent approval by the Food and Drug Administration (FDA) of ponatinib (ICLUSIG®) in combination with chemotherapy represents a significant milestone in the management of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). This article provides oncologists with a detailed analysis of the efficacy, safety profile, and dosing considerations associated with this newly approved regimen. Efficacy Evaluation: PhALLCON Trial The efficacy of ponatinib (ICLUSIG®) in newly diagnosed Ph+ ALL was evaluated in the PhALLCON trial, a randomized, active-controlled, multicenter study involving 245 adult patients. Participants were randomized in a 2:1 ratio to receive either ponatinib…